135 related articles for article (PubMed ID: 1312304)
1. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates.
Azzi A; Ciappi S; Zakvrzewska K; Morfini M; Mariani G; Mannucci PM
Am J Hematol; 1992 Mar; 39(3):228-30. PubMed ID: 1312304
[TBL] [Abstract][Full Text] [Related]
2. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa.
Rubinstein R; Karabus CD; Smuts H; Kolia F; Van Rensburg EJ
Haemophilia; 2000 Mar; 6(2):93-7. PubMed ID: 10781195
[TBL] [Abstract][Full Text] [Related]
5. Parvovirus B19 transmission by a high-purity factor VIII concentrate.
Wu CG; Mason B; Jong J; Erdman D; McKernan L; Oakley M; Soucie M; Evatt B; Yu MY
Transfusion; 2005 Jun; 45(6):1003-10. PubMed ID: 15935000
[TBL] [Abstract][Full Text] [Related]
6. Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate.
Matsui H; Sugimoto M; Tsuji S; Shima M; Giddings J; Yoshioka A
J Pediatr Hematol Oncol; 1999; 21(1):74-6. PubMed ID: 10029819
[TBL] [Abstract][Full Text] [Related]
7. Parvovirus B19 transmission by heat-treated clotting factor concentrates.
Blümel J; Schmidt I; Effenberger W; Seitz H; Willkommen H; Brackmann HH; Löwer J; Eis-Hübinger AM
Transfusion; 2002 Nov; 42(11):1473-81. PubMed ID: 12421221
[TBL] [Abstract][Full Text] [Related]
8. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates.
Lefrère JJ; Mariotti M; Thauvin M
Lancet; 1994 Jan; 343(8891):211-2. PubMed ID: 7904670
[TBL] [Abstract][Full Text] [Related]
9. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group.
Mannucci PM; Gdovin S; Gringeri A; Colombo M; Mele A; Schinaia N; Ciavarella N; Emerson SU; Purcell RH
Ann Intern Med; 1994 Jan; 120(1):1-7. PubMed ID: 7504424
[TBL] [Abstract][Full Text] [Related]
10. [Severe parvovirus B19 infection in an immunocompetent child with hemophilia A].
Coumau E; Peynet J; Harzic M; Béal G; Castaigne S; Leverger G; Foucaud P
Arch Pediatr; 1996 Jan; 3(1):35-9. PubMed ID: 8745824
[TBL] [Abstract][Full Text] [Related]
11. Transmission of human parvovirus B19 by coagulation factor concentrates.
Williams MD; Cohen BJ; Beddall AC; Pasi KJ; Mortimer PP; Hill FG
Vox Sang; 1990; 58(3):177-81. PubMed ID: 2160147
[TBL] [Abstract][Full Text] [Related]
12. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates.
Bartolomei Corsi O; Azzi A; Morfini M; Fanci R; Rossi Ferrini P
J Med Virol; 1988 Jun; 25(2):165-70. PubMed ID: 2839609
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
Mannucci PM
Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
[TBL] [Abstract][Full Text] [Related]
14. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation.
Soucie JM; Siwak EB; Hooper WC; Evatt BL; Hollinger FB;
Transfusion; 2004 Aug; 44(8):1179-85. PubMed ID: 15265122
[TBL] [Abstract][Full Text] [Related]
15. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma.
Koenigbauer UF; Eastlund T; Day JW
Transfusion; 2000 Oct; 40(10):1203-6. PubMed ID: 11061856
[TBL] [Abstract][Full Text] [Related]
16. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.
Laurian Y; Dussaix E; Parquet A; Chalvon-Demersay A; d'Oiron R; Tchernia G
Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):449-53. PubMed ID: 7753615
[TBL] [Abstract][Full Text] [Related]
17. Human parvovirus PARV4 in clotting factor VIII concentrates.
Fryer JF; Hubbard AR; Baylis SA
Vox Sang; 2007 Nov; 93(4):341-7. PubMed ID: 18070279
[TBL] [Abstract][Full Text] [Related]
18. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients.
Mauser-Bunschoten EP; Zaaijer HL; van Drimmelen AA; de Vries S; Roosendaal G; van den Berg HM; Lelie PN
Vox Sang; 1998; 74(4):225-7. PubMed ID: 9691402
[TBL] [Abstract][Full Text] [Related]
20. Parvovirus B19 infection in patients with hemophilia.
Ragni MV; Koch WC; Jordan JA
Transfusion; 1996 Mar; 36(3):238-41. PubMed ID: 8604509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
